Publications by authors named "Maria C Piccirillo"

Claim this Profile
C
Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.
Maria Lucia Iacovino, Simone Talucci, Laura Arenare, Andrea Caglio, Andrea Canciello, Maria Carmela Piccirillo

J Transl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study.
Gerardo Rosati, Maria Carmela Piccirillo, Guglielmo Nasti, Alfonso De Stefano, Chiara Carlomagno

Drugs Aging· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi

J Thorac Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.
Caterina Caminiti, Giuseppe Maglietta, Laura Arenare, Raimondo Di Liello, Gessica Migliaccio, Maria Carmela Piccirillo

Breast· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal notice to .
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio, Maria Carmela Piccirillo

Lancet Reg Health Eur· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio, Maria Carmela Piccirillo

Lancet Reg Health Eur· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio, Maria Carmela Piccirillo

Lancet Reg Health Eur· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio, Maria Carmela Piccirillo

Lancet Reg Health Eur· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Quincy Chu, Francesco Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo

Lancet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi

J Thorac Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Lesley Seymour

J Thorac Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis.
Alessandro Morabito, Edoardo Mercadante, Paolo Muto, Giuliano Palumbo, Anna Manzo, Maria Carmela Piccirillo

JCO Oncol Pract· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trial.
Valentina D'Angelo, Maria Carmela Piccirillo, Massimo Di Maio, Ciro Gallo, Cristina Bucci

Front Med (Lausanne)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF Inhibitors in Non-Small Cell Lung Cancer.
Vincenzo Sforza, Giuliano Palumbo, Priscilla Cascetta, Guido Carillio, Anna Manzo, Maria Carmela Piccirillo

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Survivorship: the Role of Rehabilitation According to the International Classification of Functioning Disability and Health-a Scoping Review.
Monica Pinto, Dario Calafiore, Maria Carmela Piccirillo, Massimo Costa, Ozden Ozyemisci Taskiran

Curr Oncol Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi

J Thorac Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurbinectedin in small cell lung cancer.
Anna Manzo, Vincenzo Sforza, Guido Carillio, Giuliano Palumbo, Agnese Montanino, Maria Carmela Piccirillo

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
Crescenzo D'Alterio, Anna Spina, Laura Arenare, Paolo Chiodini, Maria Napolitano, Maria Carmela Piccirillo

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials.
Raimondo Di Liello, Maria Carmela Piccirillo, Laura Arenare, Piera Gargiulo, Clorinda Schettino

Life (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Maria Carmela Piccirillo

Int J Gynecol Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system.
Silvia Riva, Laura Arenare, Massimo Di Maio, Fabio Efficace, Vincenzo Montesarchio, Maria Carmela Piccirillo

BMJ Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella

J Transl Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.
Daniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, Rossella De Cecio, Laura Arenare, Maria Carmela Piccirillo

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET Inhibitors in Non-Small-Cell Lung Cancer.
Priscilla Cascetta, Vincenzo Sforza, Anna Manzo, Guido Carillio, Giuliano Palumbo, Maria Carmela Piccirillo

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The opportunity of patient-journey studies for academic clinical research in oncology.
Francesco Perrone, Raimondo Di Liello, Piera Gargiulo, Laura Arenare, Lorenzo Guizzaro, Maria Carmela Piccirillo

BMJ Open· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis